EGFR and non-small cell lung carcinoma: Here, in order to assess outcomes in a larger cohort, we report a combined analysis of three phase IIIb studies of afatinib in EGFR TKI-naïve patients with EGFRm+ NSCLC treated in a setting similar to daily clinical practice (19, 20).